How do you determine the optimal timing and patient profile for introducing targeted therapies in IDH-mutant glioma?
Explore case-based debates on integrating novel IDH inhibitors into the treatment algorithm based on tumor grade, molecular markers, and individual patient characteristics.
▶️
mdsc.pe/4nSpgIb